Literature DB >> 3112230

Cellular and humoral immunity to Leishmania major in genetically susceptible mice after in vivo depletion of L3T4+ T cells.

M D Sadick, F P Heinzel, V M Shigekane, W L Fisher, R M Locksley.   

Abstract

Depletion of critical T cell subsets in vivo by treatment with anti-L3T4 antibody (mAb GK1.5) enables BALB/c mice to heal subsequent Leishmania major infection. To investigate the mechanisms by which healing is established, anti-leishmania cellular and humoral responses in anti-L3T4-treated BALB/c mice were compared to those in control BALB/c and genetically resistant C57BL/6 mice. Lymph node and spleen cells were harvested from L. major-infected animals at 1, 2, 3, 4, and 8 wk post-infection and examined in vitro for concanavalin A- or L. major antigen (either promastigote or amastigote)-induced IFN-gamma production. Serum was harvested for Western blot analysis against L. major promastigote antigens. Lymph node cells from resistant C57BL/6 mice generated Leishmania antigen-induced IFN-gamma that was maximal by 3 wk; spleen cell IFN-gamma production peaked a week later. Lymph node and spleen cells from susceptible BALB/c mice generated minimal levels of IFN-gamma activity in response to Leishmania antigen stimulation throughout the experiment. Lymph node and spleen cells from BALB/c mice which had been pretreated with GK1.5 generated IFN-gamma in response to Leishmania antigens in vitro at levels that approached those generated by C57BL/6 mice. When splenic mRNA from infected animals was hybridized with a labeled murine IFN-gamma cDNA probe, there were corresponding differences in the amount of IFN-gamma message present, demonstrating that the differences observed in IFN-gamma production in vitro were also apparent in vivo, and were due to differences in transcription. In contrast to C57BL/6 mice which generated only a limited array of Leishmania-specific antibodies, BALB/c mice produced antibodies which reacted with a large number of Leishmania antigens. The GK1.5-treated BALB/c mice developed Leishmania-specific antibodies at a slower rate than did untreated BALB/c mice. However, by 8 wk after infection, the humoral responses of the anti-L3T4-treated BALB/c mice and the untreated BALB/c mice were comparable. These data document the kinetics of ascending immunity from the draining local lymph nodes to the spleen and confirm, both in vitro and in vivo, the correlation of IFN-gamma production with control of infection in leishmaniasis. Further, an L3T4+ T cell subpopulation may be incriminated in the failure of genetically susceptible BALB/c mice to activate curative cell-mediated immunity in response to Leishmania antigens.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3112230

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  31 in total

1.  Requirement of CD4-positive T cells for cellular recruitment to the lungs of mice in response to a particulate intratracheal antigen.

Authors:  J L Curtis; P K Byrd; M L Warnock; H B Kaltreider
Journal:  J Clin Invest       Date:  1991-10       Impact factor: 14.808

2.  Depletion of L3T4+ (CD4+) T lymphocytes prevents development of resistance to Toxoplasma gondii in mice.

Authors:  F G Araujo
Journal:  Infect Immun       Date:  1991-05       Impact factor: 3.441

Review 3.  How diverse--CD4 effector T cells and their functions.

Authors:  Yisong Y Wan; Richard A Flavell
Journal:  J Mol Cell Biol       Date:  2009-05-28       Impact factor: 6.216

4.  Repertoires of antibodies to culture filtrate antigens in different mouse strains infected with Mycobacterium bovis BCG.

Authors:  K Huygen; L Ljungqvist; R ten Berg; J P Van Vooren
Journal:  Infect Immun       Date:  1990-07       Impact factor: 3.441

5.  Pretreatment with recombinant Flt3 ligand partially protects against progressive cutaneous leishmaniasis in susceptible BALB/c mice.

Authors:  I B Kremer; M P Gould; K D Cooper; F P Heinzel
Journal:  Infect Immun       Date:  2001-02       Impact factor: 3.441

6.  Immunomodulatory effects of anti-CD4 antibody in host resistance against infections and tumors in human CD4 transgenic mice.

Authors:  D J Herzyk; E R Gore; R Polsky; K L Nadwodny; C C Maier; S Liu; T K Hart; A G Harmsen; P J Bugelski
Journal:  Infect Immun       Date:  2001-02       Impact factor: 3.441

7.  Parasite exposure elicits a preferential T-cell response involved in protective immunity against Eimeria species in chickens primed by an internal-image anti-idiotypic antibody.

Authors:  B S Bhogal; E B Jacobson; H Y Tse; D M Schmatz; O J Ravino
Journal:  Infect Immun       Date:  1989-09       Impact factor: 3.441

8.  Effect of CD4 monoclonal antibody in vivo on lesion development, delayed-type hypersensitivity and interleukin 3 production in experimental murine cutaneous leishmaniasis.

Authors:  F Y Liew; S Millott; R Lelchuk; S Cobbold; H Waldmann
Journal:  Clin Exp Immunol       Date:  1989-03       Impact factor: 4.330

9.  Cytokine regulation of murine leishmaniasis: interleukin 4 is not sufficient to mediate progressive disease in resistant C57BL/6 mice.

Authors:  M D Sadick; N Street; T R Mosmann; R M Locksley
Journal:  Infect Immun       Date:  1991-12       Impact factor: 3.441

10.  Identification of IL-17-producing FOXP3+ regulatory T cells in humans.

Authors:  Kui Shin Voo; Yui-Hsi Wang; Fabio R Santori; Cesar Boggiano; Yi-Hong Wang; Kazuhiko Arima; Laura Bover; Shino Hanabuchi; Jahan Khalili; Ekaterina Marinova; Biao Zheng; Dan R Littman; Yong-Jun Liu
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-09       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.